| First Author | Luan C | Year | 2019 |
| Journal | J Invest Dermatol | Volume | 139 |
| Issue | 4 | Pages | 859-867 |
| PubMed ID | 30395847 | Mgi Jnum | J:318538 |
| Mgi Id | MGI:6860055 | Doi | 10.1016/j.jid.2018.07.046 |
| Citation | Luan C, et al. (2019) Potentiation of Psoriasis-Like Inflammation by PCSK9. J Invest Dermatol 139(4):859-867 |
| abstractText | Psoriasis is a systemic inflammatory disease, associated with metabolic disorders, including high level of low-density lipoprotein. PCSK9, which promotes the degradation of low-density lipoprotein receptors and, therefore, the increased concentration of circulating low-density lipoprotein, is also involved in inflammation. This study aims to examine the role of PCSK9 in psoriasis and to investigate the potential of topically applying small interfering RNA targeting Pcsk9 as a psoriasis treatment. We investigated the expression of PCSK9 in lesions of psoriasis patients and imiquimod-induced psoriatic reactions in Pcsk9-knockout and Pcsk9 small interfering RNA-treated mice, and we also used cultured human keratinocytes to investigate the role of PCSK9 in regulating cell proliferation and apoptosis. We found that PCSK9 is overexpressed in psoriatic lesions and that suppressing Pcsk9 can decrease the inflammatory reaction induced by imiquimod treatment and inhibit hyperproliferation of keratinocytes. We also found that suppressing PCSK9 can significantly alter the cell cycle and induce apoptosis of human keratinocytes. Taken together, our findings indicate that PCSK9 plays an important role in psoriasis and may be a therapeutic target. |
